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Eye movement desensitization and reprocessing (EMDR) is a well-established treatment
for post-traumatic stress disorder. Recent research suggested that it may be effective
in treating depressive disorders as well. The present study is part of a multicenter
randomized-controlled trial, the EDEN study, in which a homogenous group of 30
patients was treated to test whether EMDR plus treatment as usual (TAU) would achieve
superior results compared to TAU only in a psychosomatic-psychotherapeutic inpatient
treatment setting. Both groups were assessed by the Beck Depression Inventory-
II (BDI-II) and the Global Severity Index and depression subscale of the Symptom
Checklist 90-Revised. The EMDR + TAU group improved significantly better than
the TAU group on the BDI-II and Global Severity Index, while a marginally significant
difference favoring the EMDR + TAU group over the TAU group was found on the
depression subscale. In the EMDR + TAU group, seven out of 14 patients improved
below nine points on the BDI-II, which is considered to be a full remission, while four out
of 16 in the TAU group did so. These findings confirm earlier suggestions that EMDR
therapy may provide additional benefit in the treatment of depression. The present study
strengthens the previous literature on EMDR therapy in the treatment of depression due
to the randomized-controlled design of the EDEN study.
Keywords: depression, eye movement desensitization and reprocessing, randomized-controlled trial, Beck
Depression Inventory, symptom checklist 90-revised
INTRODUCTION
According to the often-considered study of the World Health Organization (World Health
Organization [WHO], 2012), depressive disorders belong to the most prevalent and disabling
diseases of all: At least 350 million people are affected by depressive disorders worldwide, almost
one million of which commit suicide every year (Murray and Lopez, 1996; Greden, 2001).
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Due to their frequency and severity, depressive disorders thereby
belong to the biggest worldwide challenges of the psychiatric
profession.
Treatment options for depressive spectrum disorders are
partially favorable, but also partially problematic. Although
pharmacological as well as psychotherapeutic treatment
approaches are available, incomplete remission and high long-
term relapse rates remain for many patients. Research has
shown that psychotherapeutic interventions can be helpful –
not only in mild and moderate depression, but also in cases
of severe and chronic depression (Nemeroff et al., 2003). In
a meta-analysis by Vittengl et al. (2007), however, 29% of
those who responded to acute-phase cognitive-behavioral
therapies relapsed after 1 year, and 54% relapsed after 2 years.
Furthermore, the available pharmacological treatments for
depressive disorders are associated with several issues. Although
these treatments improved in the last 20 years, the optimism
associated especially with recent antidepressants like the
SSRI class (e.g., Fluoxetine) has faded due to meta-analyses on
antidepressant pharmacotherapy showing only a slight advantage
over placebo. The greatest treatment success was shown in a
study with predominantly severe depression (Fournier et al.,
2010), wherein antidepressant treatment was often associated
with side effects (e.g., weight gain and other problems lasting over
time; Hirschfeld, 2003; Kripalani et al., 2007; Reid and Barbui,
2010). Though a systematic review based on 31 randomized
studies has shown that relapse rates may be reduced by 50%
with antidepressant medication (of all classes; Geddes et al.,
2003), the very high likelihood of depressive relapses often
leads to lifelong medication. Incidentally, depressive symptoms
remaining after treatment and the degree of treatment resistance
relating to the previous depressive episode are considered risk
factors for a relapse (Reid and Barbui, 2010). Additionally, it
is noteworthy that between 10 and 20% of depressive episodes
become chronic or are considered treatment resistant to
standard depression treatments. Furthermore, the danger of
relapsing increases not only when specific personality traits,
dysfunctional beliefs, and/or cognitive schemas are present, but
also in response to experience of trauma or critical life events.
In summary, the current treatment effects and especially the
high relapse rates in acute depressive episodes are unsatisfactory.
However, adjunctive psychotherapeutic treatment has been
found to reduce the risk of relapse by 22% when compared with
pharmacological antidepressant treatment alone (Vittengl et al.,
2007).
In order to further improve treatment effects and lower
relapse rates, it may be necessary to put greater emphasis on the
importance of traumatic experiences and adverse life events for
the development and progression of depression. For instance,
it is a well-known clinical observation that depression may
be triggered and maintained by stressful life events. Recent
research indicates that chronic and acute stressors like traumatic
experiences and other adverse life experiences like loss, hurt,
and humiliation can trigger depressive disorders (Heim and
Nemeroff, 2001; McFarlane, 2010). Especially so-called primary
episodes are often closely linked with a specific psychosocial
stressor, while later depressive episodes may be triggered by
far smaller events or even come about without any noticeable
stressor (Post, 1992). Risch et al. (2009) could also show the
strong influence of stressful life events in a large meta-analysis:
According to their analysis, stressful life events are the only risk
factor to be significantly correlated with the onset of depression.
For instance, a serotonin transporter gene polymorphism as a
neurobiological vulnerability factor alone, or in combination
with adverse life events, did not significantly correlate with the
occurrence of depressive episodes. Similarly, a large case-control
study found an association in which the risk for depression
doubled when violent victimization was experienced in early life
(Wise et al., 2001). Furthermore, Mandelli et al. (2015) found that
childhood emotional abuse and neglect correlate with the highest
risk for experiencing depressive disorders in adulthood, even
when compared to other forms of childhood trauma like physical
abuse or sexual abuse. Some researchers have also brought up the
notion that adverse life events could have similarly severe effects
on depression as the far more stressful traumatic experiences
described in the type A criterion definition of the DSM (Gold
et al., 2005). This is also supported by data from a survey of 832
people (Mol et al., 2005), which showed that stressful life events
can generate at least as many post-traumatic stress disorder
(PTSD) symptoms as classical traumatic events according to the
type A criterion. For stressful life events dating up to 30 years
back, the PTSD symptomatology was more pronounced than for
traumatic events that corresponded with the type A criterion.
In light of the previously presented research, it makes sense
to develop complementary therapy strategies. Eye movement
desensitization and reprocessing (EMDR) therapy is a promising
candidate for such a complementary strategy that could provide
an additional benefit in the treatment of depression. The
treatment was first developed by Shapiro (1989, 2001) after a
serendipitous observation of the relaxing effect of horizontal
saccadic eye movements was initially used to treat PTSD, and
has proven its effectiveness in this field (Bisson and Andrew,
2007). It targets memories of critical life events as well as
traumatic experiences and enables the psychotherapeutic focus
on maladaptive cognitive patterns. Though Shapiro (1989, 2001)
at first observed the therapeutic effectiveness of EMDR in
PTSD, she increasingly observed effects on other symptoms
(e.g., anxiety), which led to EMDR being used to treat other
disorders that may also be based on, or exacerbated by,
unprocessed and maladaptively stored memories of stressful
life events. The main principle of EMDR therapy thus is the
reprocessing of maladaptively stored (pathogenic) memories that
produce symptoms when activated by sensory cues (Centonze
et al., 2005). The effectiveness of EMDR has also been
shown by neurobiological research showing a normalization
of brain activity in the sense of more adaptive information
processing (AIP) after EMDR treatment (Pagani et al., 2013).
The reprocessing part of EMDR is initiated and maintained
by bilateral stimulation – mainly through eye movements, but
alternatively also through bilateral alternating auditory or tactile
stimulation.
While its efficacy as a PTSD treatment has been well-
researched, the effectiveness of EMDR in the treatment of
depression has only recently begun to receive systematic research
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attention (Hofmann et al., 2014; Hase et al., 2015). Previously,
what stood out in studies of PTSD was that EMDR concomitantly
improved comorbid depressive symptoms along with the main
PTSD symptomatology. For instance, several case reports showed
that depressive patients could be successfully treated with either
EMDR therapy alone or with EMDR therapy as an adjunct to
other approaches (Manfield, 1998; Tinker and Wilson, 1999;
Sun et al., 2004; Broad and Wheeler, 2006; Shapiro and Grand,
2009; Rosas Uribe et al., 2010; Grey, 2011). For instance, two
adolescents with major depression were successfully treated with
EMDR therapy only (three and seven sessions, respectively)
and showed stable improvements in a 3-month follow-up
examination (Bae et al., 2008). In both cases, EMDR was
successfully applied in the processing of relationship losses or
changes. Such events (relationship losses or negative changes)
also seem to be a specific risk factor for depressive disorders.
In a large retrospective study, losses, separation events, and
humiliating events were strongly associated with an increased
risk for depressive episodes (Kendler et al., 2003). Going beyond
case reports, van der Kolk et al. (2007) conducted a randomized
clinical trial comparing the effectiveness of fluoxetine with EMDR
treatment and placebo in a PTSD population and found the
EMDR group to have significantly lower depression scores than
the fluoxetine group. This led them to conclude that once “. . .the
trauma is resolved, other domains of psychological functioning
appear to improve spontaneously” (van der Kolk et al., 2007,
p. 8). This result had previously been found by similar controlled
studies, such as a study of Power et al. (2002) in which PTSD
patients were either treated with cognitive behavioral therapy
(CBT) or with EMDR (there was a wait list control group).
Both treatment groups experienced significant improvements in
PTSD and comorbid depression symptoms, which also showed at
6-month follow-up.
Out of these research results, the idea emerged that EMDR
therapy may be a helpful adjunct treatment in the treatment
of depression. To test this, a larger study investigated whether
different results may be obtained in depressive patients without
an explicit trauma history when adding additional EMDR therapy
in comparison with CBT treatment (Hofmann et al., 2014).
In this study with a group of 42 depressive patients, one
group was treated with CBT (21 patients) and the other one
with CBT + EMDR (seven additional EMDR sessions). The
CBT + EMDR group showed more complete remissions and
a greater reduction in Beck Depression Inventory (BDI) scores
than the CBT only group. In another matched-pairs study in a
clinical setting (Hase et al., 2015), 11 out of 16 patients (68%)
in the EMDR group showed a complete remission of depressive
symptomatology at the end of treatment. The EMDR group also
showed a greater reduction of depressive symptoms than the CBT
only group. However, it should be noted that the generalizability
of the findings was limited due to the small sample and lack of a
randomized-controlled design.
On the whole though, these previously mentioned studies
provided first empirical indications that EMDR therapy may have
significant positive effects in the treatment of depressive episodes
and recurrent depressive disorders. This provided an incentive
to conduct higher-quality clinical studies like the present study,
which presents the first randomized-controlled clinical trial
looking at adjunctive EMDR therapy in the treatment of
depression. In this study, we proposed the following hypotheses:
(1) EMDR therapy produces an additional benefit over
treatment as usual in the treatment of patients with acute
depressive episodes.
(2) EMDR therapy increases the proportion of complete
remissions in the treatment of patients with acute
depressive episodes.
MATERIALS AND METHODS
Study Setting and Study Participants
The study was part of a Europe-wide multicenter study (EDEN)
examining the effects of EMDR in the treatment of depressive
disorders. The aim of the study was to replicate previous
results showing that EMDR contributes to the improvement of
depressive disorders in a larger patient group. The study also
aims to show, via the analysis of follow-ups recorded in the
EDEN study, whether the number of depressive relapses can
be reduced. The study was carried out in accordance with the
recommendations of the ethical guidelines of the Declaration of
Helsinki with written informed consent being obtained from all
participants. The protocol was approved by the ethics committee
of the University of Kiel.
Table 1 presents sample demographic information. The
sample consisted of 30 inpatients of a psychiatric and
psychosomatic rehabilitation clinic receiving treatment for a
moderate to severe depressive episode. The treatment as usual
(TAU) group comprised 16 patients and the EMDR+ TAU group
comprised 14 patients. Included ICD-10 diagnoses were F32.1
(three in TAU, four in EMDR + TAU group), F33.0 (one in
TAU, none EMDR + TAU group), F33.1 (ten in TAU, nine in
EMDR+ TAU group), F33.2 (one in TAU, one in EMDR+ TAU
group), and F33.4 (one in TAU, none in EMDR + TAU group).
All participants were patients (privately insured through the
German Armed Forces) in the department of psychosomatic
medicine and psychotherapy at the Diana rehabilitation center
clinic, Bad Bevensen, Germany. In the context of standard
admission procedures with clinical anamnesis and gathering of
existing psychopathology according to AMDP, the diagnosis of
depression (ICD-10 F32.x and F33.x) was made. Patients that
were eligible for the study were extensively informed about
the chances and risks of an additional treatment with the
EMDR method and gave their written informed consent. In the
case of consent, they were added to the EDEN database and
concomitantly randomized in one of the two treatment groups
(see below). The EMDR treatment was administered according
to manualized EMDR procedures (Shapiro, 2001) and the EDEN
study protocol (Hofmann et al., 2016).
Inclusion criteria were: The presence of a depressive episode
or a recurrent depressive disorder according to clinical diagnostic
findings, at least mild depression with a BDI-score of more
than 12, and current psychopharmacological antidepressant
treatment.
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TABLE 1 | Sample demographics by treatment group.
TAU (%) EMDR + TAU (%) Sig.1
Children None 11 (69) 7 (50) 0.30
One or more 5 (31) 7 (50)
Education Post-secondary 5 (31) 4 (29) 0.93
Post-secondary
(vocationally
restricted)
1 (6) 1 (7)
Secondary 9 (56) 7 (50)
Lower secondary 1 (6) 2 (14)
Marital
status
Unmarried 9 (56) 3 (21) 0.13
Married 6 (38) 8 (57)
Divorced/Separated 1 (6) 3 (21)
Sex Male 14 (88) 13 (93) 1.00
Female 2 (13) 1 (7)
Age 39.23 (10.02) 40.32 (9.25) 0.78
Frequencies with corresponding percentages (rounded to the closest integer)
given in parentheses. For Age, mean and standard deviations (in parentheses) are
provided instead of frequencies and percentages. 1The p-value for the Children by
Treatment Group comparison was derived from a chi-squared test. The p-values for
Education by Treatment Group and Marital Status by Treatment Group were derived
from Fisher’s exact test as expected cell totals below five occurred in the respective
contingency tables. The p-value for Age by Treatment Group was derived from an
independent-samples t-test.
Exclusion criteria were: Acute suicidality, detected
comorbidities like, for example, personality disorders or
addiction disorders, psychotic symptomatology, complex PTSD,
and a pronounced dissociative symptomatology (detected with
scores of >25% in the standardized questionnaire “DES-II,”
disorders of the eye (e.g., acute retinal detachment or recent eye
surgery), or simultaneously running judicial trials or statutory
pension insurance scheme applications to prevent external
obstacles to a successful treatment. The only dropout criteria
were the emergence of acute suicidality or the withdrawal of
informed consent.
In the early diagnostics, complex PTSD was selected as an
exclusion criterion to minimize risks and side effects in the study.
As was shown in multiple studies (Frustaci et al., 2010; Rosas
Uribe et al., 2010; Hofmann et al., 2014), EMDR treatment is
well tolerated when controlling for contraindications. All study
participants were offered the opportunity to receive up to two
outpatient follow-up care visits in the rehabilitation center, if
needed.
Procedure of Data Collection
The beginning of the data collection started with the admission
to the inpatient psychosomatic treatment in the department of
psychosomatic medicine and psychotherapy of the Diana clinic.
For randomization, the EDEN database was used. The EDEN
database was developed for the EDEN study, which has been
running since 2012 as a multicenter study in six centers in
four European countries (Italy, Germany, Spain, and Turkey). In
this study, the EDEN database randomized participants into the
control group (TAU) and the treatment group (TAU + EMDR).
The project also focuses on the research question of whether
the number of relapses may be reduced by EMDR treatment
through a planned follow-up taking place 1 and 2 years after
treatment. The measurements with the instruments described
below were partly taken on a weekly basis (BDI), and partly
only at beginning and end of treatment (SCL-90-R, see below).
An assessor who was blind to participants’ assigned conditions
administered all of these measurements, which were computer-
based.
Beck Depression Inventory II
The Beck Depression Inventory II (BDI-II; Hautzinger et al.,
2006) is a self-report instrument to assess of the severity
of depressive symptomatology and its change in response to
treatment (the study comparison considers admission and end-
of-treatment scores). The sum score of this test can range from
0 to 63 points. If the patient checks multiple answer options
in one item, the highest selected number of points will count
toward the sum score. A score of less than nine points falls
into the normal range. Scores between nine and 13 indicate a
minimal severity of depressive symptoms. Scores between 14
and 19 indicate a mild depressive disorder. Scores of 20 or
higher are considered clinically relevant, with scores between 20
and 28 indicating a moderate depressive disorder, and scores
higher than 29 indicating severe depression. The BDI-II maps
a wide spectrum of depressive symptomatology (Beck et al.,
1961) and features high reliability and validity. Moderate to high
correlations show concurrent validity with different depression
scales. Albeit no exact value is listed for the diagnosis of a
depressive disorder, a comparing statement is possible.
SCL-90-R
The Symptom-Check-List 90 Items Revised-Version (SCL-90-R;
Derogatis et al., 1973) is an instrument to record subjective
impairment due to physical and mental symptoms within a time
frame of 7 days. The test is also suitable for checking the course
of a disorder. The Global Severity Index (GSI) gives an indication
of the overall burden for any given patient with symptoms on all
scales. Of the nine factorial scales, the depression subscale was
additionally used in the study. Measurements are given in the
form of standardized t-values here. They fall within the normal
population when they are between 40 and 60. The mean score is
thus 50 (SD = 10). Values of 60–64 are considered to be slightly
elevated, 65–69 considerably elevated, 70–74 strongly elevated,
and 75–80 very strongly elevated.
Treatment Methods
The TAU group comprised 16 patients with depressive
symptomatology satisfying the in- and exclusion criteria listed
above. These patients were treated in the usual clinical setting
with a psychodynamic or behavioral group therapy (participation
twice or 90 min per week) and a standard individual therapy.
They all received antidepressant medication (which is listed as an
inclusion criterion above).
The EMDR + TAU group comprised 14 patients that were
treated in the same clinical setting as the TAU group, receiving the
same TAU treatment including antidepressant pharmacotherapy.
In addition, it was planned to process one unprocessed memory
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with EMDR per week, which requires one to two sessions
per week. It is important to highlight that the EMDR group
did not receive as many standard individual therapy sessions
as the TAU group due to the administration of EMDR. The
EMDR + TAU group received between 4 and 12 EMDR sessions
in total (M = 8.5, SD = 2.41).
The so-called EMDR standard protocol is split into eight
treatment phases. In the application of the EMDR therapy, the
work is usually conducted in the three domains of past, present,
and future. In the domain of the past, dysfunctionally stored
pathogenic memories are being reprocessed. In the domain of
the present, experience-related nightmares, triggers, and also
abnormal behaviors are targets of the EMDR treatment. In
the domain of the future, the therapy targets the change of
avoidance behavior and the development of respective behavioral
alternatives, and anxiety concerned with a possible future
depressive relapse. In all areas, dysfunctionally stored and
unprocessed information is the target of the EMDR treatment.
The eight treatment phases according to the EMDR standard
protocol are ideally structured as:
Phase 1: History and Treatment Planning – In phase 1,
the precise anamnesis and clinical history are recorded. In
doing this, it is especially important to give an indication for
or against the EMDR method, which also means it is about
the exclusion of contraindications. This is also done with
the help of specific test diagnostics.
Phase 2: Preparation – In phase 2, a precise treatment
plan is made and the patient receives extensive information
about the method. If necessary, the learning of relaxation
or imaginative techniques, as well as pharmacological
treatment may take place at this point to ensure sufficient
stabilization.
Phase 3: Assessment – In phase 3, the dysfunctional stressful
memory in question is activated in its affective, sensory, and
cognitive components. In doing this, the entire pathogenic
memory is activated through the controlled and fractional
activation of partial networks (according to LeDoux, 2001).
Phase 4: Desensitization – The method then proceeds
to the central phase of the processing work, where the
patient connects with the memory. At the same time,
bilateral stimulation is applied here, mostly by therapist-
guided eye movements. From here on, the process typically
proceeds idiosyncratically and individually. The quick
associative succession of changing affective and sensory
impressions and thoughts is characteristic here. This often
leads to a notable relief in the patient, although intensively
experienced affects or physical symptoms (affective or
somatic reactions) may also be registered in the meantime.
The gradual relief experienced in this offers a great
advantage for the processing in the patient. The pressure
generated by the mobilized memory material remains well-
manageable therapeutically.
Phase 5: Installation – Once the degree of stress has
sufficiently decreased in phase 4 and the positive cognition
that was identified in phase 3 has clearly gained strength (as
checked by the therapist), a strengthening of the positive
cognition is enforced by bilateral stimulation. In doing so,
it appears to be sustainably cognitively installed.
Phase 6: Body Scan – The body scan serves to search
for potentially persisting sensory memory. In case any of
them are encountered, they will be reprocessed by adding
bilateral stimulation.
Phase 7: Closure – Since the experience that the patient
makes from phase 4 to phase 6 is typically very impressive,
it is extensively discussed with the therapist afterwards. The
possibility of reprocessing material that surfaced during the
session or was not completely processed is also presented to
the patient.
Phase 8: Re-evaluation – This phase serves as a platform for
patient feedback about changes after previous sessions.
Statistical Analysis
An analysis of covariance (ANCOVA) was run for BDI-II, SCL-
90-R GSI, and SCL-90-R depression subscale scores as dependent
variables with treatment group as the main independent variable.
The analyses controlled for type of diagnosis (single/recurrent
depression), patient age, total number of days in treatment, and
the score on the respective dependent variable at the beginning
of treatment. Interactions between treatment group and the
covariates type of depression, patient age, and total number of
days in treatment were included in the model. A simple contrast
with the TAU group as the reference group was used to examine
potential differences between the two groups.
RESULTS
There were no statistically significant differences between the
scores on the recorded outcome measures (BDI-II, SCL-90-R
depression subscale, and SCL-90-R GSI) and age between the
two groups at the beginning of treatment. Table 2 presents
descriptive statistics for said outcome measures and patient age at
the beginning and at the end of treatment, grouped by treatment.
Table 3 presents descriptive statistics and correlations between
variables of interest. The distribution of single and recurrent
depressive episodes was not significantly different between TAU
and EMDR + TAU (Fisher’s exact test: p = 0.68). Table 4
presents the results of the ANCOVA of BDI-II scores at
the end of treatment. The analysis controlled for the type
of depression (single versus recurrent episode), patient age,
total number of days in treatment, and BDI-II scores at the
TABLE 2 | Mean and standard deviations for both groups.
Baseline End of treatment
BDI-II TAU 23.02 (5.86) 16.59 (11.35)
EMDR + TAU 22.43 (8.75) 12.21 (11.23)
SCL-90R depression
subscale
TAU 72.06 (6.53) 65.07 (9.23)
EMDR + TAU 69.79 (8.20) 59.71 (13.71)
SCL-90R GSI TAU 70.63 (6.00) 62.40 (8.97)
EMDR + TAU 66.71 (6.01) 58.79 (12.91)
Standard deviations are given in parentheses. NTAU = 16, NEMDR + TAU = 14.
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TABLE 3 | Descriptive statistics and correlation matrix.
M SD 1. 2. 3. 4. 5. 6. 7. 8.
1. BDI-II (Beginning) 22.74 7.22
2. BDI-II (End) 14.55 11.32 0.58∗∗
3. SCL-90-R depression subscale (Beginning) 71.00 7.32 0.62∗∗∗ 0.68∗∗∗
4. SCL-90-R depression subscale (End) 62.48 11.72 0.55∗∗ 0.88∗∗∗ 0.73∗∗∗
5. SCL-90-R GSI (Beginning) 68.80 6.22 0.59∗∗ 0.64∗∗∗ 0.85∗∗∗ 0.62∗∗∗
6. SCL-90-R GSI (End) 60.66 11.00 0.59∗∗ 0.86∗∗∗ 0.74∗∗∗ 0.95∗∗∗ 0.71∗∗∗
7. Treatment group −0.04 −0.20 −0.16 −0.23 −0.32 −0.17
8. Age 39.74 9.52 −0.49∗∗ −0.45∗ −0.36∗ −0.53∗∗ −0.20 −0.48∗∗ 0.06
9. Total number of days in treatment 53.97 16.34 0.52∗∗ 0.14 0.15 0.29 0.03 0.31 0.33 −0.33
N = 30, M = Mean, SD = Standard deviation. Significance denoted by ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.
beginning of treatment. A significant effect of treatment group
[F(1,21) = 6.30, p < 0.05, η2p = 0.23] was examined by a
simple contrast, which showed that the EMDR + TAU group
scored significantly lower than the TAU group on adjusted end
of treatment BDI-II scores (contrast value = 74.97, p = 0.02,
η2p = 0.23). Figure 1 illustrates this contrast. Furthermore, a
significant covariate effect was found for BDI-II scores at the
beginning of treatment [F(1,21) = 8.85, p < 0.05, η2p = 0.30].
Additionally, a significant interaction between treatment group
and patient age was found [F(1,21) = 6.40, p < 0.05, η2p = 0.23].
This interaction can be interpreted as the difference between
EMDR + TAU and TAU concerning the magnitude of the
association between age and end-of-treatment BDI-II scores.
Precisely speaking, the association between patient age and end-
of-treatment BDI-II scores is more positive in the TAU group
than in the EMDR+ TAU group. It is presented in Figure 2.
Table 5 displays the results of the ANCOVA of SCL-90-R
depression subscale scores at the end of treatment. The analysis
controlled for the type of depression, patient age, total number
of days in treatment, and SCL-90-R depression subscale scores
at the beginning of treatment. A marginally significant effect
for treatment group [F(1,20.87) = 3.44, p = 0.08, η2p = 0.14]
was examined by a simple contrast, which showed that the
EMDR + TAU group had marginally significantly lower end-
of-treatment SCL-90-R depression subscale scores than the TAU
group (contrast value = 46.02, p = 0.08, η2p = 0.15). Figure 3
illustrates this contrast.
Moreover, significant covariate effects for patient age
[F(1,20) = 5.66, p < 0.05, η2p = 0.22] and beginning-of-
treatment SCL-90-R depression subscale scores were found
[F(1,20) = 13.41, p < 0.01, η2p = 0.40]. Apart from that, a
significant interaction between treatment group and patient
age was found [F(1,20) = 6.78, p < 0.05, η2p = 0.25]. This
interaction can be interpreted as the difference in magnitude of
the association between patient age and beginning-of-treatment
SCL-90-R depression subscale scores. After examining the
respective coefficient, it emerged that the association between
patient age and SCL-90-R depression subscale scores was more
positive in the TAU group than in the EMDR + TAU group.
Figure 4 illustrates this.
Table 6 displays the results of the ANCOVA of SCL-90-R GSI
scores at the end of treatment. The analysis controlled for the type
of depression, patient age, total number of days in treatment, and
SCL-90-R GSI scores at the beginning of treatment. A significant
effect for treatment group [F(1,20.95) = 4.37, p< 0.05, η2p = 0.17]
was examined by a simple contrast, which showed that the
EMDR + TAU group scored significantly lower on the SCL-90-
R GSI than the TAU group (contrast value = 47.47, p < 0.05,
η2p = 0.18). Figure 5 displays this graphically. Moreover,
significant covariate effects for patient age [F(1,20) = 6.27,
p < 0.05, η2p = 0.24] and beginning-of-treatment GSI scores
were found [F(1,20) = 21.04, p < 0.001, η2p = 0.51]. Apart
from that, a significant interaction effect between treatment
group and patient age was found [F(1,20) = 8.00, p < 0.05,
η2p = 0.29]. This interaction can be interpreted as the difference
in magnitude of the association between patient age and
beginning-of-treatment SCL-90-R GSI scores. After examining
its coefficient, it turned out that the association between patient
age and SCL-90-R GSI scores was more positive in the TAU
group than in the EMDR + TAU group. Figure 6 illustrates
this.
The results consisted of the changes between the beginning
and the end of the treatment regarding psychological tests (BDI-
II, SCL-90-R depression subscale, and SCL-90-R GSI). In the
EMDR + TAU group, a relatively more clear improvement
compared to the TAU group showed. In seven of the 14
patients in the EMDR + TAU group, the BDI-II score dropped
below nine points, falling within the normal range and being
considered a full remission. In four patients, a clear improvement
showed with scores dropping below 20, which is considered
a slight depressive symptomatology. One patient showed mild
improvement, remaining in the range of moderate depressive
symptoms. In two patients, no improvements showed according
to the BDI-II.
Of the 16 TAU group patients, four patients improved
below nine points on the BDI-II, which can be considered
a full remission. In five patients, an improvement showed,
letting their scores drop below 14 into in the range of a
minimally depressive symptomatology. In two patients, an
improvement showed that put them in the mildly depressive
symptom range (below 20 points). One patient improved to
fall within 20 to 28 points, which classifies as moderately
severe depressive symptomatology. Two patients remained
without improvement in the severely depressed range with
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TABLE 4 | ANCOVA of BDI-II (End).
Source Mean square F Significance η2p
Treatment group 456.43 6.30 0.02 0.23
Type of diagnosis 100.91 13.44 0.24 0.95
Age 89.68 1.22 0.28 0.06
Total number of days in
treatment
50.75 0.69 0.42 0.03
BDI-II (Beginning) 650.58 8.85 0.01 0.30
Treatment group∗age 470.47 6.40 0.02 0.23
Treatment group∗total
number of days in
treatment
291.36 3.96 0.06 0.16
Treatment group∗type of
diagnosis
8.67 0.12 0.74 0.01
N = 30.
scores higher than 29. In two patients, the BDI-II worsened
from the moderately severe to the severe range (over 29
points).
This means that 50% of the 14 patients who received
EMDR + TAU showed a complete remission at the end of
treatment. In the TAU group with 16 patients, only 25% of scores
indicated a complete remission. The EMDR + TAU group thus
showed a greater reduction of depressive symptoms than the TAU
group, exhibiting significantly lower BDI-II scores at the end of
treatment (see Figure 1). Furthermore, a significant interaction
between treatment group and patient age was found. The effect
indicated age was more strongly negatively related with end-of-
treatment BDI-II scores in the EMDR + TAU group than in the
TAU group. This suggests that older people may have benefited
more from EMDR treatment than younger people.
On the SCL-90-R depression subscale, the EMDR + TAU
group also showed lower end-of-treatment scores than the TAU
group. In the EMDR+ TAU group, 12 out of 14 patients showed
a mild to marked improvement of those scores. One patient
showed a mild worsening, and one patient scored the same as
at the beginning of treatment. In the TAU group, 11 patients
showed a mild to marked improvement. In three patients, no
improvement showed relative to their scores at the beginning of
treatment. One patient in this group missed this testing session.
Hence, the EMDR + TAU group showed a somewhat greater
reduction of depressive symptoms on the SCL-90-R depression
subscale than the TAU group, albeit only marginally statistically
significant in the ANCOVA analysis. This difference is shown in
Figure 3.
An interaction effect similar to the one found in the BDI-
II score analysis showed on the SCL-90-R depression subscale.
It involved patient age and treatment group, indicating that
higher age was more strongly associated with lower SCL-90-R
depression subscale scores in the EMDR + TAU group than in
the TAU group.
In the SCL-90-R GSI score analysis, the EMDR + TAU group
(14 patients) showed mild to marked improvements at the end
FIGURE 1 | Adjusted mean BDI-II scores for TAU and EMDR + TAU at end of treatment.
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FIGURE 2 | Comparison of regression slopes for age and BDI-II (end of
treatment) between the two treatment groups.
TABLE 5 | ANCOVA of SCL-90-R depression subscale (End).
Source Mean square F Significance η2p
Treatment group 143.37 3.44 0.08 0.14
Type of diagnosis 112.60 1.57 0.41 0.58
Age 233.34 5.66 0.03 0.22
Total number of days in
treatment
98.34 2.38 0.14 0.11
SCL-90-R depression subscale
(Beginning)
553.21 13.41 <0.01 0.40
Treatment group∗age 279.73 6.78 0.02 0.25
Treatment group∗total number
of days in treatment
41.62 1.01 0.33 0.05
Treatment group∗Type of
diagnosis
75.31 1.83 0.19 0.08
N = 29.
of treatment in 13 patients and a worsening of global symptom
severity in one patient. In the TAU group with 16 patients, 13
patients showed mild to marked improvements, as measured
by lower SCL-90-R GSI scores at the end of treatment. In two
patients, stagnation showed with scores remaining unchanged
from beginning to end of treatment. One patient missed the final
testing, leading to missing data on this outcome.
Both groups thus showed improvements in SCL-90-R GSI
scores from the beginning to the end of treatment. Like on
the BDI-II, the SCL-90-R GSI scores in the EMDR + TAU
group were lower than in the TAU group. Similar to the BDI-
II and SCL-90-R depression subscale analyses, an interaction
emerged in the analysis of SCL-90-R GSI scores between age
and treatment group. This effect indicated that the negative
relationship between age and end-of-treatment SCL-90-R GSI
scores was stronger in the EMDR + TAU group than in the TAU
group.
No side effects were reported during the treatment in the
context of the study. This indicates that the EMDR treatment was
well tolerated by the patients. Hyperarousal was hardly observed
in the sessions. Intense affect was experienced in some sessions,
but could be stabilized and reprocessed. The time frame of a
maximum of 60 min per session was sufficient to process most
of the treated stressful memories.
DISCUSSION
The present study is embedded in the larger context of the
EDEN multicenter study, which investigates whether EMDR
treatment has a beneficial effect in the treatment of depression.
Moreover, the collection of catamnesis data helps to examine
whether EMDR may reduce the number of relapses. This research
is necessary due to the high worldwide prevalence of depressive
disorders and the not yet satisfactory outcomes in the treatment
of depression that are characterized by high relapse rates.
Furthermore, the present study is relevant because it represents
the first study of higher methodological quality regarding this
topic, reporting on a randomized-controlled clinical trial. In
order to provide more homogenous treatment conditions, the use
of antidepressant medication was an inclusion criterion in the
study, leading to a more naturalistic sample.
The results of this study show that patients suffering from
depression benefit from adjunctive EMDR in the acute depression
treatment. In the experimental group (EMDR+ TAU), there was
a significantly better improvement of BDI-II scores than in the
control group (TAU only). Of 14 patients in the experimental
group, the BDI-II score of seven patients improved below nine
points, which equals a complete remission. This compares to four
patients improving below nine points in the control group with
16 patients. The experimental group also showed better results on
the SCL-90-R depression subscale. A mild to clear improvement
was shown in 12 out of 14 patients. In the slightly larger control
group, mild to clear improvements showed in 11 patients. Finally,
the SCL-90-R GSI scores also showed a clearly more positive
result in the experimental group than in the control group.
In the experimental group, 13 patients showed mild to clear
improvements. In the control group, mild to clear improvements
showed for 12 patients.
The interaction between treatment group and patient age
that was observed on all outcome variables (BDI-II, SCL-90-R
depression subscale, and SCL-90-R GSI) showed that there was a
greater age effect in the experimental group than in the control
group, meaning that older patients tended to have relatively
lower symptom scores than younger patients in the experimental
group than in the control group. Possible explanations for
this could be the greater life experience of older patients, the
decreasing number of foreign missions for soldiers as they get
older, the often higher rank of older soldiers within the armed
forces, or the proximity to retirement. Regarding this, it would
be interesting to compare this sample with patients from a
different health care provider (e.g., a public health insurance
provider).
The model of AIP (Shapiro, 2001) offers a potential
explanation for the beneficial effects of EMDR therapy observed
in the present study. The AIP model postulates that stressful
events may be dysfunctionally stored and that these stressful
memories may consequently form the basis of mental disorders
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FIGURE 3 | Adjusted mean SCL-90-R depression subscale scores for TAU and EMDR + TAU at end of treatment.
FIGURE 4 | Comparison of regression slopes for age and SCL-90-R
depression subscale (end of treatment) between the two treatment groups.
such as depression. This means that even non-A criterion
types of stressful memories can be dysfunctionally stored in
memory networks. It also postulates that in reprocessing patients’
dysfunctionally stored stressful memories, they ultimately get
adaptively integrated into memory networks. Many of these
stressful memories in depressive disorders were memories of
losses, separations, or humiliations, but also experiences of
TABLE 6 | ANCOVA of SCL-90-R GSI scores (End).
Source Mean square F Significance η2p
Treatment group 161.93 4.37 0.05 0.17
Type of diagnosis 17.63 0.21 0.72 0.16
Age 227.62 6.27 0.02 0.24
Total number of days in
treatment
80.21 2.21 0.15 0.10
GSI (Beginning) 764.16 21.04 <0.001 0.51
Treatment group∗Age 290.46 8.00 0.01 0.29
Treatment group∗total number
of days in treatment
28.58 0.79 0.39 0.04
Treatment group∗type of
diagnosis
89.62 2.47 0.13 0.11
N = 29. Scores were rounded to two decimals. The exact significance value for
treatment group was below 0.05 (p = 0.048).
childhood emotional abuse and neglect, which are typical
forms of stressful memories that appear to be related with
the occurrence of depressive disorders (Mandelli et al., 2015).
This fits well with studies that showed that victims of adverse
life events do not remember A criterion events as more
traumatic than other adverse life events (Gold et al., 2005)
or in other terms, that the so-called type A criterion events
were not perceived as more stressful than the so-called non-
type A criterion events. In summary, the AIP model suggests
a profound effect of EMDR therapy due to the processing
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FIGURE 5 | Adjusted mean SCL-90-R GSI scores for TAU and EMDR + TAU at end of treatment.
FIGURE 6 | Comparison of regression slopes for age and SCL-90-R GSI
scores (end of treatment) between the two treatment groups.
of pathogenic memories, as described by Centonze et al.
(2005).
The present study contributes to the literature not only by
showing the beneficial effect of EMDR in the treatment of
depression, but also by corroborating previous findings with a
stronger research design. For example, compared with a previous
matched-pair study (Hase et al., 2015), the present study was
advantageous with regard to the randomized-controlled design.
Furthermore, a disadvantage of the matched-pair study was
that the BDI-II tests were only given to the 11 patients of the
experimental group. This precluded the comparison of both
groups regarding the rate of complete remissions, as the BDI-II
tests were not given to the control group due to limited resources.
Thus, the study was unable to make a scientific comparison
and could only hint at the effectiveness of adjunctive EMDR
treatment of depressive patients. The somewhat older, similar
study of Hofmann et al. (2014) did not randomize the sample,
either. It may also have been limited by the limited clinical
experience of the psychotherapists in both groups and the fact
that the control group consisted of patients who received CBT
in the same clinic at the same time, but did not constitute a
randomized treatment group. A further possible disadvantage
was the unequally distributed use of antidepressants in the
patients of the study. In the control group, 6 of 21 patients
received antidepressants, while nine of 21 in the experimental
group received antidepressant medication. The literature around
EMDR therapy in the treatment of depression is likely to be
strengthened by further studies using strong methodologies to
examine the effect of EMDR in the treatment of depression in
the context of the EDEN multicenter study.
There are several limitations to the present study. First, its low
sample size limits the generalizability of the results and requires
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replication in order to see whether the present findings would
show again in a larger sample, for example, in a multicenter
study comparison, which is also planned for the EDEN study.
Second, this study sampled a population of patients that were
insured by the armed forces, leading to an over-representation
of men. In order to account for this limitation and include more
female participants, future research could sample patients insured
by health care companies other than those exclusively working
with military personnel. A third limitation concerns the fact that
patients self-reported the severity of their depressive symptoms.
More objective measures, or independent observer ratings of
depressive symptoms could have strengthened the findings of this
study.
In future research, one could study the efficacy of EMDR in
the treatment of depression without concomitant antidepressant
medication in an outpatient sample. This would be possible
in mildly to moderately depressed patients. Furthermore, the
expected meta-analysis of the EDEN multicenter study remains a
prospect for the further scientific investigation of EMDR therapy
in the treatment of depressive disorders. This will also show
whether the positive effects of EMDR found in the present study
can be supported in a greater population. Lastly, one could still
examine the hypothesized beneficial effect of EMDR therapy in
reducing the depressive relapse rate at follow-up.
CONCLUSION
Given the predicted worldwide increase of depression and the
limited success of TAU, it is important to develop adjunctive
therapy strategies. The present randomized study examined
whether EMDR therapy produces a positive effect in the
treatment of depression beyond TAU. On the BDI-II and the GSI
score of the SCL-90-R, additional EMDR treatment produced
significant improvements over the effects of TAU, while it
produced marginally significant improvements over TAU on
the depression subscale of the SCL-90-R. Given the previously
high rate of non-responders to TAU, the present study thus
suggests that EMDR may improve treatment outcomes when
added to TAU. The present study significantly contributes to
the knowledge base in the field as it is the first to have used
a randomized-controlled study design to examine the efficacy
of EMDR in the treatment of depression. However, its low
sample size reduces the generalizability of the results and
calls for larger future studies to replicate the effects found in
this study. Follow-up comparisons to the present study will
reveal whether adjunctive EMDR therapy also produced more
sustainable treatment effects as manifested by fewer depressive
relapses at follow-up.
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